Literature DB >> 26440974

Microarray CGH analysis of hematological patients with del(20q).

Chunxiao Wu1, Jinlan Pan2, Huiying Qiu1, Yongquan Xue1, Suning Chen1, Yafang Wu1, Jun zhang1, Shuxiao Bai1, Yong Wang1, Juan Shen1, Yanlei Gong1.   

Abstract

Deletion of the long arm of chromosome 20 is a common abnormality underlying hematological malignancy. We analyzed 21 patients with hematologic diseases confirmed to carry the del(20q) by conventional cytogenetics and fluorescence in situ hybridization using microarray comparative genomic hybridization (aCGH). Seventeen patients were positive for del(20q), but this deletion was not detected in four patients. All deletions detected were interstitial of which continuous deletions were seen in 12 patients and discrete deletions in five. Three commonly deleted regions (CDRs) and two commonly retained regions (CRRs) were defined: CDR1 spanning 3.05Mb (34560497-37608229) within 20q11.23, CDR2 spanning 1.76Mb (37851501-39615698) within 20q12, CDR3 spanning 116Kb (48120412-48236791) within 20q13.13, CRR1 spanning 1.1Mb (29374726-30428250) within 20q11.21, and CRR2 spanning 2.5Mb (60484668-62963548) within 20q13.33. Duplications of retained regions (20q11.21) were found in five cases with similar erythroid hyperplasia (2 M6, 3 MDS). Moreover, duplication of 20p13-p11.21 was also found in two cases with M6. Using the CDRs and CRRs, we identified the candidate genes we searched for using the UCSC Genome Browser. Our data suggest that aCGH analysis is useful for more precisely defining breakpoints on 20q. Further work is required to identify candidate pathogenic genes within these CDRs and CRRs.

Entities:  

Keywords:  Commonly deleted regions; Commonly retained regions; Hematological malignancies; Microarray comparative genomic hybridization; del(20q)

Mesh:

Year:  2015        PMID: 26440974     DOI: 10.1007/s12185-015-1872-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  16 in total

1.  The paradox of 20q11.21 amplification in a subset of cases of myeloid malignancy with chromosome 20 deletion.

Authors:  Ruth N Mackinnon; Carly Selan; Meaghan Wall; Elizabeth Baker; Harshal Nandurkar; Lynda J Campbell
Journal:  Genes Chromosomes Cancer       Date:  2010-11       Impact factor: 5.006

Review 2.  Cytogenetic Nomenclature: Changes in the ISCN 2013 Compared to the 2009 Edition.

Authors:  A Simons; L G Shaffer; R J Hastings
Journal:  Cytogenet Genome Res       Date:  2013       Impact factor: 1.636

3.  Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances.

Authors:  S Solinas-Toldo; S Lampel; S Stilgenbauer; J Nickolenko; A Benner; H Döhner; T Cremer; P Lichter
Journal:  Genes Chromosomes Cancer       Date:  1997-12       Impact factor: 5.006

4.  Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes.

Authors:  F A Asimakopoulos; N J White; E Nacheva; A R Green
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

5.  Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG).

Authors:  A J Bench; E P Nacheva; T L Hood; J L Holden; L French; S Swanton; K M Champion; J Li; P Whittaker; G Stavrides; A R Hunt; B J Huntly; L J Campbell; D R Bentley; P Deloukas; A R Green
Journal:  Oncogene       Date:  2000-08-10       Impact factor: 9.867

6.  Refinement of the commonly deleted segment in myeloid leukemias with a del(20q).

Authors:  P W Wang; K Iannantuoni; E M Davis; R Espinosa; M Stoffel; M M Le Beau
Journal:  Genes Chromosomes Cancer       Date:  1998-02       Impact factor: 5.006

7.  L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability.

Authors:  Nadia Gurvich; Fabiana Perna; Andrea Farina; Francesca Voza; Silvia Menendez; Jerard Hurwitz; Stephen D Nimer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-13       Impact factor: 11.205

8.  Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions.

Authors:  Nathalie Douet-Guilbert; Audrey Basinko; Frédéric Morel; Marie-Josée Le Bris; Valérie Ugo; Patrick Morice; Christian Berthou; Marc De Braekeleer
Journal:  Ann Hematol       Date:  2008-03-19       Impact factor: 3.673

9.  Frequency and photographs of HGM11 chromosome anomalies in bone marrow samples from 3,996 patients with malignant hematologic neoplasms.

Authors:  G W Dewald; C R Schad; V C Lilla; S M Jalal
Journal:  Cancer Genet Cytogenet       Date:  1993-07-01

10.  Molecular genetics of myeloid leukemia: identification of the commonly deleted segment of chromosome 20.

Authors:  D Roulston; R Espinosa; M Stoffel; G I Bell; M M Le Beau
Journal:  Blood       Date:  1993-12-01       Impact factor: 22.113

View more
  2 in total

Review 1.  Techniques for detecting chromosomal aberrations in myelodysplastic syndromes.

Authors:  Qibin Song; Min Peng; Yuxin Chu; Shiang Huang
Journal:  Oncotarget       Date:  2017-05-09

2.  Reduced PLCG1 expression is associated with inferior survival for myelodysplastic syndromes.

Authors:  Masayuki Shiseki; Mayuko Ishii; Mari Miyazaki; Satoko Osanai; Yan-Hua Wang; Kentaro Yoshinaga; Naoki Mori; Junji Tanaka
Journal:  Cancer Med       Date:  2019-11-21       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.